Natera (NTRA) Announces Publication of Findings from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study

Core Insights - Natera, Inc. (NASDAQ:NTRA) is recognized as a high growth large cap stock, with recent positive developments in clinical research and stock price upgrades [1][3] Clinical Research Developments - The publication of findings from the randomized, phase III CALGB (Alliance)/SWOG 80702 study in JAMA Oncology indicates that for patients with detectable postoperative circulating tumor DNA (ctDNA), the addition of celecoxib to standard chemotherapy significantly improved disease-free survival (DFS) and overall survival (OS) [2] - Natera's Signatera has been highlighted as a valuable prognostic marker for disease recurrence and survival in colorectal cancer patients [2] - In collaboration with Quantum Leap Healthcare Collaborative, Natera published new findings from the I-SPY 2 trial in Nature Communications, demonstrating how Signatera can enhance risk assessment in early-stage breast cancer patients resistant to neoadjuvant therapy [4] Stock Performance and Analyst Ratings - Jefferies raised the price target for Natera's stock from $230.00 to $275.00 while maintaining a "Buy" rating, citing the company's consistent performance in exceeding expectations and raising guidance [3] - Factors contributing to growth include an increased average selling price from commercial coverage, new indications, and guidelines, with the American College of Obstetricians and Gynecologists (ACOG) potentially acting as a catalyst for non-invasive prenatal testing (NIPT) [3]